Back to search

Aristotle University Of Thessaloniki (AUTH)

Ρόλος μιτοχονδιακών πρωτεϊνών στην παθοφυσιολογία και θεραπευτική εκφυλιστικών παθήσεων

Abstract

dc:description

One of the most frequent causes of mitochondrial disorders is cytochrome c oxidase (COX) deficiency. COX (complex IV in mitochondrial electron chain reaction) consists of thirteen (13) subunits that are organized as holoenzyme located within the inner mitochondrial membrane. One of the proteins involved in COX assembly is Sco2, encoded by nuclear SCO2 gene and then transported into the mitochondria, where contributes to COX assembly. Impaired COX assembly leads to COX deficiency, lack of cell respiration and cell death. This is quite critical in ageing and degenerative disorders. Mutations in SCO2 gene have been detected in newborns suffering of lethal encephalopathy characterized by COX deficiency, muscular weakness and hypertrophic cardiomyopathy (Papadopoulou et al., 1999). The present thesis work has been designed to: a) investigate the effects of two pathogenic point mutations (E140K, S225F), found in the human SCO2 gene, on the physical state of mitochondrial Sco2 protein and its copper binding capacity, and b) apply the Protein Transduction technology (PTD) to transduce wild type recombinant Sco2 protein into mitochondria of cultured glioma U-87 MG cells. Within the scope of present thesis, the point mutations (E140K, S225F) of SCO2 gene were studied. Wild type and mutants of SCO2 gene were cloned and expressed as heterologous proteins in E. coli cells, using fusion cloning and expression vector system (IMPACTTM-CN, pTYB11). Wild type and mutated forms of Sco2 were prepared as recombinant proteins and examined for their physical state, conformation and their ability to bind cooper. SDS-PAGE electrophoresis analysis revealed that Sco2E140K και Sco2S225F mutant forms of Sco2 protein are quite different from their wild type counterpart in physical state and copper capacity. Circular dichroism (CD) spectroscopy and thermal denaturation studies confirmed differences, supporting the motion that the two point mutations alter both the physical state and the binding capacity of Sco2 proteins (Foltopoulou et al., 2004). Combinatorial Cloning Technology complemented by the novel Protein Transduction Technology (PTD) was applied in order to attempt targeted intracellular delivery of human recombinant Sco2 protein in eukaryotic cells. Wild type recombinant Sco2 fusion protein, bearing also the TAT domain as PTD, His-tag and HA-tag, produced in genetically modified E. coli cells (Foltopoulou et al., 2006). This hererologous protein was resolved, refolded and delivered in culture of U-87 MG glioma cells. Preliminary immunofluorescent data, followed by subcellular localization, SDS-PAGE electrophoresis and Western Blotting analysis revealed that recombinant Sco2 protein had been delivered into mitochondria of mammalian cells. These experiments may allow correction of the clinical phenotype of SCO2 mutations via protein therapy (PTD-Technology). Finally, these studies represent a suitable model system for intracellular delivery of biopharmaceutical proteins as a new therapeutic approach of genetic diseases.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Φολτοπούλου, Παρθένα
  • Foltopoulou, Parthena

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/20476

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Φολτοπούλου, Παρθένα; Foltopoulou, Parthena. Ρόλος μιτοχονδιακών πρωτεϊνών στην παθοφυσιολογία και θεραπευτική εκφυλιστικών παθήσεων. Aristotle University Of Thessaloniki (AUTH), 2007. http://hdl.handle.net/10442/hedi/20476